These recent findings suggest the use of FRβ-targeting NPs for other tumor types, and also suggest the addition of several ligands (ie, anti-PD-L2) to improve the selectivity of the NPs towards the right population of TAMs. The gene discussed is FOLR2; the disease is neoplasm.